Skip to main content
. Author manuscript; available in PMC: 2020 Jul 29.
Published in final edited form as: Rev Cardiovasc Med. 2020 Jun 30;21(2):163–179. doi: 10.31083/j.rcm.2020.02.597

Figure 4: Stem cell-based therapy, gene transfer and epigenetic therapy as promising innovative strategies for treating pulmonary hypertension.

Figure 4:

Recent preclinical studies suggested that stem cell-based therapies, gene transfer and epigenetic-based therapies may offer a new perspective in the treatment of PAH. Administration of endothelial progenitor cells (EPCs), mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), intratracheal administration of inhaled-adenovirus encoding for BMPR2 or gene delivery of adeno-associated virus (AAV) serotype 1 encoding for human SERCA2a prevented and reversed the development of PH in preclinical animal models of PAH by blocking cardiac/arterial remodeling and improving hemodynamic abnormalities (RVSP, mPAP). Increasing evidence suggests that epigenetic-based therapies, such as DNMT, HDAC and BET inhibitors, may be of great therapeutic potential for treating PAH.